On this episode of Managed Care Cast, we speak with the president and CEO of the Leapfrog Group about her organization’s partnership with the Healthcare Transformation Alliance and how transparency and employer leverage may shape the transition toward value-based health care.
As the health care industry continues to combat health and cost-related issues exacerbated by the COVID-19 pandemic, employers remain a key figure in the pursuit for higher-value care. Recently, the Leapfrog Group partnered with the Health Transformation Alliance, or HTA, to help delineate high-value health care services with a particular focus on transparency and payment reform.
On this episode of Managed Care Cast, we speak with Leah Binder, president and chief executive officer of the Leapfrog Group, about her organization’s partnership with the HTA, the significance of their 20th anniversary this year, and how transparency and employer leverage may shape the transition toward value-based health care.
Listen above or through one of these podcast services:
Read more:
How Halting Telehealth Waivers May Impact Cost, Deferral in Care
Reforming Oncology Care Payments: Interviews From the QCCA Leadership Summit
Implications of Justice Barrett’s Confirmation on Employment Law Rulings, ACA Case
How Employers Think About Addressing Rising Prices of Health Insurance
How Can Health Care Purchasers, Providers Better Coordinate to Improve Value-Based Care Delivery?
Over Time, Health Care Costs Move to Forefront for All Patients
CMS, HHS Finalize Mandatory Model to Boost Kidney Transplant Access, Equity
December 2nd 2024The 6-year mandatory Increasing Organ Transplant Access Model aims to boost kidney transplants and address disparities by incentivizing hospitals, enhancing care coordination, and measuring transplant outcome performance.
Read More
Expert Insights on How Utilization Management Drives Physician Burnout
November 26th 2024On this episode of Managed Care Cast, we speak with the author of a study published in the November 2024 issue of The American Journal of Managed Care® to explore the link between utilization management and physician burnout.
Listen
Advent of Ponatinib for Ph+ ALL Expected to Influence New Guidelines
November 29th 2024With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), updated guidelines could be on the horizon.
Read More